Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation

Bitner, Robert S.; Nikkel, Arthur L.; Otte, Stephani; Martino, Brenda; Barlow, Eve H.; Bhatia, Pramila; Stewart, Andrew O.; Brioni, Jorge D.; Decker, Michael; Moreland, Robert B.

doi:10.1016/j.neuropharm.2005.10.009

Cited by 35 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, ERK1/2 phosphorylation in the parvicellular PVH neuron may not couple directly to ␣ 1 adrenoceptors located on the neuron itself, although ␣ 1 adrenoceptor-mediated ERK1/2 activation does occur in several cell types (Zhong and Minneman, 1999;Vanhoose et al, 2002). Rather, other receptors in CRH neurons (perhaps glutamate receptors) may elevate phospho-ERK1/2 in these neurons directly (Bitner et al, 2006;Jia et al, 2006;Yuill et al, 2007). Our results using the MEK inhibitor, U0126, also show that these receptors may include those coupling to G-proteins or possessing intrinsic tyrosine kinase activity, because MEK activation, which drives ERK phosphorylation, often occurs downstream of such receptors (Cobb and Goldsmith, 1995;Della Rocca et al, 1997).…”

Section: Ne Activation Of Erk1/2 In the Pvh Requires Functional ␣1 Admentioning

confidence: 98%

Catecholaminergic Control of Mitogen-Activated Protein Kinase Signaling in Paraventricular Neuroendocrine NeuronsIn VivoandIn Vitro: A Proposed Role during Glycemic Challenges

Khan¹,

Ponzio²,

Sanchez‐Watts³

et al. 2007

J. Neurosci.

View full text Add to dashboard Cite

We show that systemic insulin and 2-DG, and PVH-targeted NE microinjections, rapidly elevated PVH phospho-ERK1/2 levels. NE increased Crh and c-fos expression, together with circulating ACTH/corticosterone. However, because injections also increased c-Fos mRNA in other brain regions, we used hypothalamic slices maintained in vitro to clarify whether NE activates PVH neurons without contribution of inputs from distal regions. In slices, bath-applied NE triggered robust phospho-ERK1/2 immunoreactivity in PVH (including CRH) neurons, which attenuated markedly in the presence of the ␣ 1 adrenoceptor antagonist, prazosin, or the MAP kinase kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene). Therefore, at a systems level, local PVH delivery of NE is sufficient to account for hindbrain activation of CRH neuroendocrine neurons during glycemic challenge. At a cellular level, these data provide the first demonstration that MAP kinase signaling cascades (MEK3 ERK) are intracellular transducers of noradrenergic signals in CRH neurons, and implicate this transduction mechanism as an important component of central neuroendocrine responses during glycemic challenge.

show abstract

Section: Ne Activation Of Erk1/2 In the Pvh Requires Functional ␣1 Admentioning

confidence: 98%

Catecholaminergic Control of Mitogen-Activated Protein Kinase Signaling in Paraventricular Neuroendocrine NeuronsIn VivoandIn Vitro: A Proposed Role during Glycemic Challenges

Khan¹,

Ponzio²,

Sanchez‐Watts³

et al. 2007

J. Neurosci.

View full text Add to dashboard Cite

show abstract

“…PD-168,077 was found able to induce penile erection also when injected into the PVN ], e.g., one of the sites where dopamine acts to induce penile erection by activating oxytocinergic neurotransmission (see [Melis et al, 1987;Argiolas and Melis 1995;Baskerville et al, 2008Baskerville et al, , 2009Melis and Argiolas, 2011]) and to induce c-FOS expression and extracellular regulated kinase (ERK) phosphorylation in this hypothalamic nucleus [Bitner et al, 2006;Baskerville et al, 2008Baskerville et al, , 2009]. The pro-erectile role of D 4 receptors has been recently confirmed by studies aimed at identifying the D2 receptor subtype (D 2 , D 3 or D 4 ) responsible for the pro-erectile effect of non selective dopamine agonists such as apomorphine and pramipexole ; but see also Collins et al, 2009;Depoortere et al, 2009].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Role of dopamine D4 receptors in copulatory behavior: Studies with selective D4 agonists and antagonists in male rats

Sanna

Contini

Melis

et al. 2015

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

“…Doses of the D 1 (SKF81297) and D 4 (PD168,077) agonists have been shown to alter memory performance after systemic administration (Browman et al, 2005;Hotte et al, 2005) and have high selectivity in vivo (Bitner et al, 2006;Gleason and Witkin, 2006). Bromocriptine is 10 and 100 times more potent at D 2 receptors vs D 3 and D 4 receptors, respectively (Seeman and Van Tol, 1993;Perachon et al, 1999), and is behaviorally active at 5.0 mg/kg (Kelsey and Carlezon, 2002).…”

Section: Drugs and Satiety Manipulationsmentioning

confidence: 99%

Dopaminergic Modulation of Risk-Based Decision Making

Onge

Floresco

2008

Neuropsychopharmacol

301

299

View full text Add to dashboard Cite

Psychopharmacological studies have implicated the mesolimbic dopamine (DA) system in the mediation of cost/benefit evaluations about delay or effort-related costs associated with larger rewards. However, the role of DA in risk-based decision making remains relatively unexplored. The present study investigated the effects of systemic manipulations of DA transmission on risky choice using a probabilistic discounting task. Over discrete trials, rats chose between two levers; a press on the 'small/certain' lever always delivered one reward pellet, whereas a press on the other, 'large/risky' lever delivered four pellets, but the probability of receiving reward decreased across the four trial blocks (100, 50, 25, 12.5%). In separate groups of well-trained rats we assessed the effects of the DA releaser amphetamine, as well as receptor selective agonists and antagonists. Amphetamine consistently increased preference for the large/risky lever; an effect that was blocked or attenuated by co-administration of either D 1 (SCH23390) or D 2 (eticlopride) receptor antagonists. Blockade of either of these receptors alone induced risk aversion. Conversely, stimulation of D 1 (SKF81297) or D 2 (bromocriptine) receptors also increased risky choice. In contrast, activation of D 3 receptors with PD128,907 reduced choice of the large/risky lever. Likewise, D 3 antagonism with nafadotride potentiated the amphetamine-induced increase in risky choice. Blockade or stimulation of D 4 receptors did not reliably alter behavior. These findings indicate that DA has a critical role in mediating risk-based decision making, with increased activation of D 1 and D 2 receptors biasing choice toward larger, probabilistic rewards, whereas D 3 receptors appear to exert opposing effects on this form of decision making.

show abstract

Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation

Cited by 35 publications

References 34 publications

Catecholaminergic Control of Mitogen-Activated Protein Kinase Signaling in Paraventricular Neuroendocrine NeuronsIn VivoandIn Vitro: A Proposed Role during Glycemic Challenges

Catecholaminergic Control of Mitogen-Activated Protein Kinase Signaling in Paraventricular Neuroendocrine NeuronsIn VivoandIn Vitro: A Proposed Role during Glycemic Challenges

Role of dopamine D4 receptors in copulatory behavior: Studies with selective D4 agonists and antagonists in male rats

Dopaminergic Modulation of Risk-Based Decision Making

Contact Info

Product

Resources

About